A detailed history of Checchi Capital Advisers, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Checchi Capital Advisers, LLC holds 1,817 shares of VRTX stock, worth $844,105. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,817
Previous 1,805 0.66%
Holding current value
$844,105
Previous $846,000 0.12%
% of portfolio
0.05%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$460.0 - $505.78 $5,520 - $6,069
12 Added 0.66%
1,817 $845,000
Q2 2024

Jul 26, 2024

BUY
$392.81 - $485.53 $46,351 - $57,292
118 Added 6.99%
1,805 $846,000
Q1 2024

Apr 25, 2024

BUY
$407.69 - $446.08 $9,784 - $10,705
24 Added 1.44%
1,687 $705,000
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $7,546 - $9,034
22 Added 1.34%
1,663 $676,000
Q3 2023

Nov 09, 2023

SELL
$338.18 - $362.46 $187,013 - $200,440
-553 Reduced 25.21%
1,641 $570,000
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $152,493 - $170,676
485 Added 28.38%
2,194 $772,000
Q1 2023

May 05, 2023

BUY
$283.23 - $323.1 $2,832 - $3,231
10 Added 0.59%
1,709 $538,000
Q4 2022

Feb 10, 2023

BUY
$285.76 - $321.48 $33,148 - $37,291
116 Added 7.33%
1,699 $490,000
Q3 2022

Nov 09, 2022

BUY
$273.83 - $305.53 $6,298 - $7,027
23 Added 1.47%
1,583 $458,000
Q2 2022

Aug 11, 2022

BUY
$234.96 - $292.55 $30,544 - $38,031
130 Added 9.09%
1,560 $437,000
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $65,761 - $77,508
297 Added 26.21%
1,430 $373,000
Q4 2021

Feb 09, 2022

SELL
$177.01 - $223.45 $18,232 - $23,015
-103 Reduced 8.33%
1,133 $249,000
Q3 2021

Nov 09, 2021

SELL
$181.39 - $202.99 $14,873 - $16,645
-82 Reduced 6.22%
1,236 $224,000
Q2 2021

Aug 06, 2021

SELL
$187.49 - $221.1 $15,186 - $17,909
-81 Reduced 5.79%
1,318 $266,000
Q1 2021

May 10, 2021

SELL
$207.02 - $241.31 $18,217 - $21,235
-88 Reduced 5.92%
1,399 $301,000
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $45,956 - $61,291
-222 Reduced 12.99%
1,487 $351,000
Q3 2020

Nov 10, 2020

BUY
$255.65 - $303.1 $26,331 - $31,219
103 Added 6.41%
1,709 $465,000
Q2 2020

Aug 12, 2020

BUY
$225.48 - $295.8 $46,899 - $61,526
208 Added 14.88%
1,606 $466,000
Q1 2020

May 07, 2020

SELL
$199.77 - $247.81 $13,784 - $17,098
-69 Reduced 4.7%
1,398 $333,000
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $1,333 - $1,791
8 Added 0.55%
1,467 $321,000
Q3 2019

Nov 06, 2019

BUY
$166.23 - $187.09 $7,979 - $8,980
48 Added 3.4%
1,459 $247,000
Q2 2019

Aug 06, 2019

BUY
$164.61 - $190.37 $38,024 - $43,975
231 Added 19.58%
1,411 $259,000
Q1 2019

May 09, 2019

SELL
$163.73 - $194.7 $9,660 - $11,487
-59 Reduced 4.76%
1,180 $217,000
Q4 2018

Feb 07, 2019

SELL
$151.91 - $192.21 $54,687 - $69,195
-360 Reduced 22.51%
1,239 $205,000
Q3 2018

Oct 29, 2018

BUY
$167.73 - $192.74 $6,541 - $7,516
39 Added 2.5%
1,599 $308,000
Q2 2018

Aug 06, 2018

BUY
$145.72 - $169.96 $20,983 - $24,474
144 Added 10.17%
1,560 $265,000
Q1 2018

May 01, 2018

BUY
$151.6 - $177.13 $11,824 - $13,816
78 Added 5.83%
1,416 $231,000
Q4 2017

Feb 02, 2018

BUY
$137.28 - $155.55 $183,680 - $208,125
1,338
1,338 $201,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Checchi Capital Advisers, LLC Portfolio

Follow Checchi Capital Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Checchi Capital Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Checchi Capital Advisers, LLC with notifications on news.